28 results
PRE 14A
AKRO
Akero Therapeutics Inc
16 Apr 24
Preliminary proxy
4:30pm
significant progress on our corporate goals for 2023, which were adopted in December 2022, including the following achievements that impacted executive … executive officers, are aligned with the interests of our stockholders and our business goals and that the total compensation paid to each of our named
8-K
EX-99.2
jk31pcnf080u9ik
13 May 21
Akero Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
7:18am
8-K
EX-99.1
f1bs8wcf0bwv6
13 Apr 21
A Global Disease, A Pioneering Treatment Corporate Presentation April 2021
8:30am
8-K
EX-99.2
b941nc2azfw6v0
22 Mar 21
Akero Announces Positive Histological Improvements in Cirrhotic NASH (F4) Patients after 16 Weeks in Extension Cohort C
4:05pm
DEF 14A
m2q07rl13d1o
27 Apr 20
Definitive proxy
7:30am
10-K
ij9fi9bpwp
16 Mar 20
Annual report
5:17pm
424B4
yvokq7arj evdtx3c9l
20 Jun 19
Prospectus supplement with pricing info
5:20pm
S-1/A
EX-10.2
clnpk2wz935
10 Jun 19
IPO registration (amended)
11:16am